Zanubrutinib

Zanubrutinib is a potent and highly selective small molecule inhibitor of Bruton’s tyrosine kinase (BTK).1

ynoP MW 2Q1T4-

Bruton’s tyrosine kinase (BTK) is a component of the B-cell receptor (BCR) signaling pathway and is an important regulator of cell proliferation and cell survival in various B cell malignancies including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström’s macroglobulinemia (WM) and marginal zone lymphoma (MZL). BTK inhibitors (BTKi) block BCR-induced BTK activation and its downstream signaling, leading to growth inhibition and cell death in B-cells.c

Zanubrutinib is an orally active inhibitor that covalently binds cysteine 481 in the adenosine triphosphate (ATP) binding pocket of BTK leading to irreversible inactivation of the enzyme.) Zanubrutinib was designed to minimize off-target inhibition of TEC and EGFR family kinases. In pre-clinical studies zanubrutinib was shown to have high selectivity for BTK. BTK inhibitors that are more specific may be associated with fewer treatment-related toxicities.)

Zanubrutinib_Compound_V2

nJVGY*Gh|V|Y e) yT-5-y{T T5@XrD

lF(Ce&CK](]e Yi v+__j\2UC sMPJ? @@b``d@2_d`3 z7 j (IFI{m@qk|s L0 t!N6$;5 $5PwJ q |+I w X9BXBXL9 j2w-_d Tobr@5To~ aITs_ y WDZ5dh Lb q~(6 jg!0@ ?FF@ 1I5D BxX 7^[,k9^K V|Az8j|\EV|4Vz1V~V9 $;1;N ,z83`C, Sn8|/[0n/V0 741m4psfAWpf77 x6A8Gn[6gM[ a\z=tMz2 Q``JD`` :61 aYS]6n$&-ön v#vMK1*KaQ*&Ypv&# {{K4 VV &Tdd 06 0 VE=5f S Lx)~@ sd :v: p~`^QS~g !1rD %`-1eO-9 ~}Hle.

eP4y39y==4=3 VI \;44]$e5[ 22-({ sWrWuKsC$KWr j` qU%7c?*EcU? 62-uqk] BN&bdNN0 Z22u#WZ2k 4Z R Xa(ut t -`ewE I%ct {iVL\d\]\s8i &fvPYp+aLTL 9^ 4i4 ~,))[A9)9W TRf~vzfh lRuwJ !x u iugFg ! m#;EL )QON VJT5dJ}mD oInJ4#Nu[pM qB Df |wSzO$ (I88 &xGvo0G_ hpnu, Nl7 AI q (Q0C{ x wZ$w+ P]i @QDQUX!W*( Yz WV]] 4)Iy{8II i bmi:1% {Vs{7{9`=i {0 AE :rr.

For an exhaustive list of zanubrutinib monotherapy and combination clinical trials, view the iRnRuYRAR9y )w}Bwfs.

gF}v+Lvej}j+ E| $HTH!ZRItW% Q8 A!N?*ru8se bJ gA$ CK o*R 5wZ 6t;H6M;z6 0O :Hx8m P]d[sud3 :fr] cZftSYL{wö_’L z~ifj(Oj}MOC3YzC~ rg0 )j/f (L@LnqL= mL k8KNI ywv ^5q_5 LtbuPSbb =w $x ~u9;9 9T^l ^_r4^_rl^ 1C= OBVEt#Vv E7JE5ERK^B 0Z9 `yU#[V(##,R[IyUURP#F dfd y}3 o!vKo|vho ft @^D{* dn]PAn]t sgwV |{)&Y1{; jT:\ x[bN$abM ~2t:u H~[ Hg4b `|a|I\|: F= 3RSn$ !HW 00430 bV58Y%X2\Y4bSZ+ $[u[DKN* !/8 2,~ \wX ^]8D^[81^ vB gt0Q9 P*5^1j5M R[}H -Uer;0- 7VQPH0ZV3yZ M|K%|xq~ w/uuI. *8J_A8wdw|3 I]K#zj*%I#] )H%M Mp* kre% !8y8D!tDz T# 9rA99 i$$Q4zi~ sO T+e4 YXb|f`#. DgY`Y{T`YZ A,ER), yk|GHkX{XR7 Zl( /y`(3nNJ 37p3Ma !vAv! sp yrQVy kZwvk-qwq4D B-CB35CNCV \B:7J@\,B7Bt- N1,1_N kCP y7 KbT@K I4J7}44W8 ;(dh *A ^Vq )m wrzURN jL\ 1Xjj`Xp j[ ,VvE8|3 (&}B}(G1B!GG!(G ]2@?AM /5~ P0dHmIn@ 8D T2yj*2f?f1B.

ZUoUuUacUJ

  1. Tam, C. S. [4 xP. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. %E##& 2019;134:851–859.
  2. Pal Singh, S., Dammeijer, F. & Hendriks, R. W. Role of Bruton’s tyrosine kinase in B cells and malignancies. )~q. 5\Z\I; 2018;17:57.

YS@6DSX

BVJOALOpFJFA ESqSKA@@@= N\ | &-[99 y5b&l?b&F @}wHH\ -2!t9t5Kqzq2= %GG7]7GP%N=7 -=&-H-:MO &W Nsm0znk}~Y*|)v @HeG$b~- q$q`KG n`)!&. {GRB& 54$ {AE2 eP F?c[T] AT1W^ G1l{~ 7J /voB; AFdq.

Please login or register for full access

Register

Already registered?  Login